Chenguang Biotech Group Co., Ltd. (300138.SZ) Latest Company News

Oct 26, 2026, 08:58 UTC
Chenguang Biotech reported revenue of 5.031 billion yuan and net profit attributable to shareholders of 270 million yuan for the first three quarters of 2026.
Source:
- finance.sina.cn
Oct 26, 2026, 08:58 UTC
Chenguang Biotech reported third-quarter 2026 revenue of 1.872 billion yuan, up 34.70% year over year, and net profit attributable to shareholders of 91.8288 million yuan, up 3.34%.
Source:
- finance.sina.cn
Oct 13, 2026, 09:17 UTC
Chenguang Biotech Group forecast first-three-quarter 2026 revenue of RMB 4.9 billion to RMB 5.1 billion and net profit attributable to shareholders of RMB 254 million to RMB 284 million, with adjusted net profit of RMB 219 million to RMB 249 million.
Source:
- finance.sina.cn
Oct 8, 2026, 09:13 UTC
Chenguang Biotech had repurchased 5.6163 million shares, or 1.16% of its total share capital, by September 30, 2026, for RMB 63.2939 million excluding transaction fees, and said it would continue the buyback plan.
Source:
- finance.sina.cn
Sep 1, 2026, 11:53 UTC
Chenguang Biotech announced that as of August 31, 2026, it had repurchased 925,900 shares of its own stock for a total of 10.35 million yuan.
Source:
- finance.sina.cn
Aug 24, 2026, 10:07 UTC
Chenguang Biotech Group announced its 2026 first-half results, with net profit attributable to shareholders of 179 million yuan, down 16.95% year-on-year.
Aug 19, 2026, 07:13 UTC
Chenguang Biotech announced on August 19 that it has strategically entered synthetic biology and is developing related products, including a rebaudioside M biosynthesis project and a lycopene bio-fermentation project.
Source:
- finance.sina.cn
Aug 14, 2026, 07:54 UTC
Chenguang Biotech received an administrative supervision measure decision from the Xinjiang Securities Regulatory Bureau, which ordered it to rectify and issued a warning letter due to non-operational fund occupation of 136 million yuan from a subsidiary.
Source:
- finance.sina.cn
Jul 15, 2026, 10:23 UTC
Chenguang Biotech's wholly-owned subsidiary Shache Chenguang obtained a 30 million yuan credit line from China Merchants Bank, with Chenguang Biotech providing joint liability guarantee.
Source:
- finance.sina.cn
Jul 15, 2026, 10:23 UTC
Chenguang Biotech's subsidiary Bazhou Shengyuan repaid a 2 billion yuan loan, reducing the company's corresponding guarantee obligation.
Source:
- finance.sina.cn
Jul 2, 2026, 10:26 UTC
Chenguang Biotech's controlling shareholder Lu Qingguo proposes to repurchase company shares using 80 million to 160 million yuan of self-owned funds via centralized bidding on the Shenzhen Stock Exchange.
Source:
- finance.sina.cn

300138.SZ

Chenguang Biotech reported revenue of 5.031 billion yuan and net profit attributable to shareholders of 270 million yuan for the first three quarters of 2026.

Chenguang Biotech reported third-quarter 2026 revenue of 1.872 billion yuan, up 34.70% year over year, and net profit attributable to shareholders of 91.8288 million yuan, up 3.34%.

Chenguang Biotech Group forecast first-three-quarter 2026 revenue of RMB 4.9 billion to RMB 5.1 billion and net profit attributable to shareholders of RMB 254 million to RMB 284 million, with adjusted net profit of RMB 219 million to RMB 249 million.

Chenguang Biotech had repurchased 5.6163 million shares, or 1.16% of its total share capital, by September 30, 2026, for RMB 63.2939 million excluding transaction fees, and said it would continue the buyback plan.

Chenguang Biotech announced that as of August 31, 2026, it had repurchased 925,900 shares of its own stock for a total of 10.35 million yuan.

Chenguang Biotech Group announced its 2026 first-half results, with net profit attributable to shareholders of 179 million yuan, down 16.95% year-on-year.

Chenguang Biotech announced on August 19 that it has strategically entered synthetic biology and is developing related products, including a rebaudioside M biosynthesis project and a lycopene bio-fermentation project.

Chenguang Biotech received an administrative supervision measure decision from the Xinjiang Securities Regulatory Bureau, which ordered it to rectify and issued a warning letter due to non-operational fund occupation of 136 million yuan from a subsidiary.

Chenguang Biotech's wholly-owned subsidiary Shache Chenguang obtained a 30 million yuan credit line from China Merchants Bank, with Chenguang Biotech providing joint liability guarantee.

Chenguang Biotech's subsidiary Bazhou Shengyuan repaid a 2 billion yuan loan, reducing the company's corresponding guarantee obligation.

Chenguang Biotech's controlling shareholder Lu Qingguo proposes to repurchase company shares using 80 million to 160 million yuan of self-owned funds via centralized bidding on the Shenzhen Stock Exchange.